2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H)-one-1,1-dioxide | 95847-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H)-one-1,1-dioxide
• 英文别名: 1,1-Dioxido-2-(4-bromobutyl)-5-chloro-1,2-benzisothiazol-3(2H)-one；2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H) one-1,1-dioxide；2-(4-bromobutyl)-5-chloro-1,2-benzisothiazol-3(2H)one 1,1-dioxide；2-(4-bromobutyl)-5-chloro-1,1-dioxido-1,2-benzothiazol-3(2H)-one；2-(4-bromobutyl)-5-chloro-1,1-dioxo-1,2-benzothiazol-3-one
• CAS: 95847-42-0
• 化学式: C₁₁H₁₁BrClNO₃S
• 分子量: 352.636
• InChiKey: KDGNARYZVWQJPV-UHFFFAOYSA-N

物化性质

• 沸点：
  502.4±60.0 °C(Predicted)
• 密度：
  1.692±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H)-one-1,1-dioxide 、 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl (3R,4S)-1-[4-(5-chloro-1,1,3-trioxo-1,2-benzothiazol-2-yl)butyl]-4-phenylpiperidine-3-carboxylate
  参考文献：
  名称：

  Selective α-1A adrenergic receptor antagonists. effects of pharmacophore regio- and stereochemistry on potency and selectivity

  摘要：

  The anti-anxiety agent ipsapirone has been shown to have modest affinity for alpha-1 receptors. We disclose the discovery of potent alpha-1a receptor subtype selective antagonists based on the ipsapirone structure which possess selectivity versus the 5-HT receptors tested. These antagonists were obtained by tethering a saccharin ring to 4-phenyl-3-carboxyethyl piperidines. The design principles which led to this structural motif are discussed. The synthesis of key analogs, their SAR, as well as results of selected in vitro and in vivo studies are described. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00451-x
• 作为产物：
  描述：

  1,4-二溴丁烷 、 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-bromobutyl)-5-chloro-1,2-benzisothiazole-3(2H)-one-1,1-dioxide
  参考文献：
  名称：

  Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists

  摘要：

  Benign prostatic hyperplasia can be managed pharmacologically with alpha-1 adrenergic receptor antagonists. Agents that demonstrate selectivity for the alpha-1a receptor subtype may offer advantages in clinical applications with respect to hypotensive side effects. The N-alkylated saccharins reported here represent a new class of subtype selective alpha-1a adrenergic receptor antagonists which demonstrate potent effects on prostate function in vivo and are devoid of blood pressure side effects. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00446-6

文献信息

• 2-pyrimidinyl-1-piperazine derivatives, processes for their preparation
  申请人：Troponwerke GmbH & Co., KG

  公开号：US04818756A1

  公开（公告）日：1989-04-04

  The invention relates to substituted 2-pyrimidinyl-1-piperazine derivatives defined herein by formula (I), processes for their manufacture, compositions containing said substituted 2-pyrimidinyl-1-piperazine derivatives as active materials and the use of said compounds and compositions as agents effecting the central nervous system. Also included in the invention are intermediates of formula (VIII) for making the active formula (I) compounds.

  这项发明涉及由以下公式（I）定义的取代2-嘧啶基-1-哌嗪衍生物，其制造方法，含有所述取代2-嘧啶基-1-哌嗪衍生物作为活性物质的组合物，以及将所述化合物和组合物用作影响中枢神经系统的药剂。该发明还包括用于制备活性公式（I）化合物的公式（VIII）的中间体。
• .alpha..sub.1a adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06096763A1

  公开（公告）日：2000-08-01

  This invention relates to novel compounds, their synthesis and use as selective .alpha..sub.1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the .alpha..sub.1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  该发明涉及新型化合物，它们的合成以及作为选择性α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是用于治疗良性前列腺增生。这些化合物在其能够放松富含α1a受体亚型的平滑肌组织方面具有选择性，同时不会引起低血压。这样的组织之一是围绕尿道内膜的组织。因此，这些化合物的一个用途是为患有良性前列腺增生的男性提供急性缓解，通过促进尿液流动。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，从而实现对良性前列腺增生影响的急性和慢性缓解。
• Alpha 1a adrenergic receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05952351A1

  公开（公告）日：1999-09-14

  This invention relates to novel compounds, their synthesis and use as selective .alpha..sub.1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the .alpha..sub.1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

  这项发明涉及新型化合物，它们的合成以及用作选择性α1a肾上腺素受体拮抗剂的用途。这些化合物的一个应用是治疗良性前列腺增生。这些化合物在其放松富含α1a受体亚型的平滑肌组织的能力上具有选择性，同时不会引起低血压。这样的组织之一位于尿道内膜周围。因此，这些化合物的一个用途是为患有良性前列腺增生的男性提供急性缓解，从而减轻尿流受阻。这些化合物的另一个用途是与人类5α-还原酶抑制剂化合物结合，以实现对良性前列腺增生影响的急性和慢性缓解。
• 2,3-dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT
  申请人：Duphar International Research B.V.

  公开号：US05462942A1

  公开（公告）日：1995-10-31

  The present invention is concerned with compounds having 5-HT1A antagonistic activity useful in treating CNS disorders and having formula 2 ##STR1## wherein R.sub.1 is halogen, lower alkyl or alkoxy, hydroxy, trifluotomethyl or cyano, m has the value 1 or 2 and n has the value 0 or 1, A represents an alkylene chain containing 2-6 C-atoms which may be substituted with one or more lower alkyl groups or a monocyclic (hetero)aryl group, and B is methylene, ethylene, carbonyl, sulfinyl, sulfonyl or sulfur, and salts thereof.

  本发明涉及具有5-HT1A拮抗活性的化合物，用于治疗中枢神经系统疾病，其化学式为2，其中R.sub.1是卤素、较低的烷基或烷氧基、羟基、三氟甲基或氰基，m的值为1或2，n的值为0或1，A代表一个含有2-6个碳原子的烷基链，可以用一个或多个较低的烷基基团或单环(杂)芳基取代，B是亚甲基、乙烯基、羰基、亚砜基、磺酰基或硫，以及其盐。
• 2,3-Dihydro-1,4-benzodioxin-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0633260A1

  公开（公告）日：1995-01-11

  The present invention is concerned with compounds having 5-HT1A antagonistic activity useful in treating CNS disorders and having formula 2 wherein R₁ is halogen, lower alkyl or alkoxy, hydroxy, trifluotomethyl or cyano, m has the value 1 or 2 and n has the value 0 or 1, A represents an alkylene chain containing 2-6 C-atoms which may be substituted with one or more lower alkyl groups or a monocyclic (hetero)aryl group, and B is methylene, ethylene, carbonyl, sulfinyl, sulfonyl or sulfur, and salts thereof.

  本发明涉及的化合物具有 5-HT1A 拮抗活性，可用于治疗中枢神经系统疾病，具有式 2 其中 R₁ 是卤素、低级烷基或烷氧基、羟基、三氟甲基或氰基、 m 的值为 1 或 2，n 的值为 0 或 1、 A 代表含有 2-6 个 C 原子的亚烷基链，可被一个或多个低级烷基或单环（杂）芳基取代，以及 B 是亚甲基、亚乙基、羰基、亚砜基、磺酰基或硫、 及其盐类。